| abstract |
The present invention relates to a pharmaceutical composition comprising as active ingredient a pharmaceutically acceptable diluent or carrier and a pharmaceutically effective amount of androst-5-ene-3b, 17b-diol or a prodrug thereof, alone or in combination with at least one active ingredient, namely dehydroepianehydro wherein the prodrug is a pharmaceutically inactive derivative of an active component that undergoes enzymatic or spontaneous conversion to the active component. The invention also encompasses a kit comprising the above pharmaceutical composition comprising a first container containing a androst-5-ene-3b, 17b-diol or a prodrug thereof, i.e. a pharmaceutically inactive derivative of the active component, which in vivo is spontaneously or enzymatically converted to the active component. and at least one further container, the further container containing at least one active component, namely progestin, estrogen, dehydroepiandrosterone, dehydroepiandrosterone sulfate, or a prodrug thereof. The above pharmaceutical compositions may be used to prevent and / or treat a variety of disorders (e.g., menopausal symptoms, osteoporosis, incontinence, uterine cancer, etc.). SHE |